CMS Proposes National Payments For Long-Term Continuous Electrocardiogram Monitoring
Analysts expect iRhythm to shift more of its long-term remote cardiac monitoring operations to its California facility to take advantage of new Medicare reimbursement rates set by the US Centers for Medicare and Medicaid Services.
You may also be interested in...
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.